The Oura IPO is not a wearables story. It is a data-monetization story wearing a hardware costume, and the market is about to price the wrong asset.
Oura confidentially filed for a US listing in May, and reporting now points to the company seeking as much as three billion dollars in the offering. The Finnish smart ring maker had already priced itself at roughly eleven billion dollars in a private round last October, more than double the valuation it carried at the end of 2024. The company has sold over 5.5 million rings and its chief executive has projected annual revenue reaching two billion dollars this year, up from around five hundred million two years earlier.
Set those numbers side by side and something odd appears. A company chasing a public valuation in the multiple billions, with revenue growing at that pace, is still generating roughly eighty percent of its sales from a physical object sold once and replaced every few years. The subscription layer, the part of the business that actually compounds, sits at around twenty percent of revenue. The market is being asked to underwrite a software multiple on top of a hardware base.
The mechanism: how a wearable IPO actually transmits through markets
Here is the part almost nobody writing about this has spelled out. An IPO of this size does not just move Oura's own stock. It resets the reference price for an entire category of comparables that public market investors have never had to mark. Garmin, Apple, Samsung and Fitbit style trackers have all had health features priced as a rounding error inside a much larger consumer electronics or services business. Oura is the first pure-play health wearable of scale to put a standalone price tag on the category itself.
Once that price tag exists, every analyst covering adjacent names has to react to it. Garmin's fitness division, which the company has said grew sharply, gets a new sum-of-the-parts anchor. Private wearables and femtech names raising their next round get a public comparable they did not have six months ago. Insurers and health systems that have been quietly running pilot programs with device data suddenly have a market-clearing number for what a health data platform with millions of daily active sensors is worth. The IPO is a pricing event for a whole vertical, not a single equity.
This is also happening inside the broadest reopening of the technology IPO window in years, with a pipeline anchored by far larger names planning to raise capital on a scale that could exceed several years of prior US listings combined. Oura is a small deal relative to that pipeline. But small deals that price first in a hot window often set the tone for how aggressively the larger ones get bid, because they are the first live test of whether public investors will actually pay up for growth stories that have spent years marked privately at venture multiples.
The second-order effect nobody is pricing
The real exposure here is not to Oura's stock. It is to the credibility of the recurring-revenue narrative that every consumer hardware company now uses to justify a software multiple. Oura has built genuine health partnerships, including insurance and clinical collaborations that extend the data moat well beyond step counting. That is a legitimate long-term asset. But a public market that has spent three years punishing hardware-plus-subscription businesses for compressed multiples is going to demand proof that the subscription attach rate keeps rising after the marketing spend of an IPO quarter fades.
If Oura prices well and trades up, the second-order effect is a repricing of every private wearables and health-data company currently marked on venture terms, forcing later-stage investors to either write up or write down positions that have had no public reference point until now. If it prices soft or breaks issue, the second-order effect runs the other way: it becomes the first data point suggesting that this year's IPO window, built almost entirely on artificial intelligence enthusiasm, has less room than advertised for anything outside that theme. Either outcome moves capital that has nothing to do with rings.
The stock everyone will watch is Oura's. The signal that actually matters is what its debut says about every other hardware-plus-subscription story waiting behind it in the pipeline.
A market-neutral book at Zentra Asset Management would not take a directional view on where Oura's shares settle. It would isolate the dispersion this creates across the comparable set: the gap between what gets re-rated up on category validation and what gets left behind because it cannot show the same subscription trajectory. That dispersion is where the mispricing sits, not in the headline valuation number.
The honest counter-case
I could be wrong about how much this matters. Wearables have a long history of hype cycles that faded once novelty wore off, from Fitbit's 2015 debut through Peloton's collapse from its own public listing highs. Oura's subscription base could plateau as competition from Apple, Samsung and Whoop intensifies on price and features, hardware margins could compress under that pressure, and the whole category comparable argument could simply not materialize if investors treat this as a one-off consumer electronics listing rather than a data platform. The counter-case is not fringe. It is the base case for most hardware IPOs of the last decade.
What would change my mind is retention data. If Oura's S-1, once public, shows subscription attach and renewal rates that are still climbing sharply rather than flattening, the platform argument holds and the category repricing follows. If those numbers look like a typical consumer electronics churn curve, this becomes a normal hardware listing and the second-order effect I am describing simply does not fire.
What I am watching next is the actual price range once it is set, and specifically whether it implies a software-like multiple on the subscription segment alone or a blended multiple across the whole business. That single detail in the prospectus will tell you more about where health-data capital is headed over the next two years than the headline valuation ever will. Komey Tetteh will be tracking the filing closely once the range is public. Where do you think the real multiple should sit: on the ring, or on the data it produces?
Common questions
Why is Oura going public now
Oura confidentially filed a draft registration statement with the SEC in May 2026 after its valuation more than doubled to roughly eleven billion dollars in an October 2025 funding round. Its listing arrives inside one of the busiest technology IPO windows in years, alongside far larger names raising capital in the same period.
How much is Oura trying to raise in its IPO
Reporting indicates Oura is seeking up to three billion dollars in its initial public offering. The exact share count and price range had not been publicly disclosed at the time of the filing.
How much of Oura's revenue comes from subscriptions versus hardware
Roughly eighty percent of Oura's revenue has come from selling the physical ring, with about twenty percent from its recurring membership subscription. That subscription share has been growing as the company adds features tied to sleep, stress and women's health.
Does Oura's IPO affect other wearable or health tech companies
A public listing of this size creates the first standalone market price for a pure-play health wearable, which analysts can then use as a reference point when valuing comparable segments at companies like Garmin, or when pricing the next funding rounds of private health-data startups. This does not guarantee those valuations move, but it removes the absence of a public comparable that has existed until now.
Who are Oura's main competitors
Oura competes most directly with Apple Watch's health features, Garmin's fitness wearables, and Samsung's device ecosystem, as well as private competitors like Whoop that focus on a similar recurring-membership model.
Is this article financial advice about buying Oura stock
No. This piece is general market commentary and analysis of how an IPO of this type transmits through markets. It is not a recommendation to buy, sell, or hold any security, and it does not state a price target or expected return.
Research that reaches you before the narrative does
One note each week connecting a global event to positioning in US markets. No paywall.
Subscribe free